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Summary
Mice deficient in the DNA damage sensor P53 display normal T cell development but eventually succumb to thymic lympho-
mas. Here,we show that inactivation of the TCRb gene enhancer (Eb) results in a block of T cell development at stageswhere
recombination-activating genes (RAG) are expressed. Introduction of the Ebmutation into p532/2mice dramatically accel-
erates the onset of lethal thymic lymphomas that harbor RAG-dependent aberrant rearrangements, chromosome 14 and 12
translocations, and amplification of the chromosomal region 9A1–A5.3. Phenotypic and genetic analyses suggest that lym-
phomas emerge through a normal thymocyte development pathway. These findings provide genetic evidence that block of
lymphocyte development at stages with RAG endonuclease activity can provoke lymphomagenesis on a background with
deficient DNA damage responses.Introduction
DNA double-strand breaks (DSBs), generated by both physio-
logical processes and physicochemical damages, represent
a serious breach of genome integrity that can trigger the onset
of cell cycle arrest, apoptosis, or tumorigenesis (Khanna and
Jackson, 2001; van Gent et al., 2001). Normally, DSBs are effi-
ciently repaired by nonhomologous end joining (NHEJ) during
the G0/G1 phase or homologous recombination during the S/
G2 phase. V(D)J recombination is a programmed DNA cleavage
and repair process by which T cell receptor (TCR) and immuno-
globulin (Ig) genes are assembled from spatially dispersed gene
segments (Fugmann et al., 2000). Recombination is initiated
when the lymphocyte-specific proteins RAG1 and RAG2 (re-
ferred to as RAG) cut DNA at the junction of coding sequences
and recombination signal sequences (RSS) (McBlane et al.,
1995), producing covalently sealed coding ends and blunt signalCANCER CELL 9, 109–120, FEBRUARY 2006 ª2006 ELSEVIER INC. DOIends (Roth et al., 1992; Schlissel et al., 1993). The resultingDSBs
are then repairedbyNHEJ, involving theDNA-dependent protein
kinase (Ku70/Ku80/DNA-PKcs), Artemis, and theXrcc4/ligase IV
complex (Chu, 1997).V(D)J recombinationhasservedasamodel
for the study of physiological DNA rearrangement and repair in
vertebrates and the effect of persistent DSBs on chromosomal
translocations and tumorigenesis (Bassing et al., 2002).
Assembly and expression of antigen receptor genes is critical
for lymphocyte development and survival. For T cells expressing
the ab TCR, development progresses from CD42CD82 (double
negative [DN]) thymocytes to CD4+CD8+ (double positive [DP])
thymocytes and finally to mature CD4+ or CD8+ (single positive
[SP]) T cells (Rothenberg and Taghon, 2005). Depending on
the status of CD44 and CD25 expression, DN thymocytes are
further divided into four successive subpopulations:
CD44+CD252 (DN1), CD44+CD25+ (DN2), CD442CD25+ (DN3),
and CD442CD252 (DN4). RAG is first expressed in DN3S I G N I F I C A N C E
DNA recombination and repair pathwaysare central to the development of normal cells, andaberrations in thesepathwayshavebeen
linked to cancer. The programmed DNA cleavage mediated by the RAG endonuclease during lymphocyte development has served
as amodel for the studyof the effect of persistent DNAbreaks onchromosomal translocations and tumorigenesis.We show that block of
T cell development at stages where RAG genes are expressed accelerates development of thymic lymphomas in mice with deficient
DNA damage responses. The lymphomas harbor RAG-dependent chromosome translocations and amplifications frequently associ-
atedwith humanhematologicalmalignancies. Thus, lymphocyte developmental arrest and the associatedpersistent RAGactivity rep-
resent a heretofore underappreciated but potentially important factor in lymphomagenesis.10.1016/j.ccr.2006.01.004 109
A R T I C L Ethymocytes to rearrange TCRb (Dudley et al., 1994; Godfrey
et al., 1994). Functional assembly of TCRb leads to expression
of the pre-TCR complex, which consists of TCRb, pTa, and
CD3 proteins and signals proliferation and differentiation of
DN thymocytes and cessation of RAG expression (Levelt and
Eichmann, 1995). In DP thymocytes, RAG is reexpressed to re-
arrange TCRa. Functional assembly of TCRa leads to expres-
sion of the complete TCR, consisting of TCRb, TCRa, and
CD3 proteins, which signals the development of SP T cells
and permanent inactivation of RAG expression. Accordingly,
failure to express pre-TCR or TCR leads to a block of thymocyte
development at the DN3 or DP stage, respectively, at which
RAG is naturally expressed. Thymocytes that fail to produce
a functional TCRb protein are eliminated by apoptosis via
a mechanism that may involve the tumor suppressor protein
P53 (Haks et al., 1999).
Normally, RAG-mediated cleavages during V(D)J recombina-
tion are tightly coupled to the efficient NHEJ repair pathway (Lee
et al., 2004) in that coding ends are rapidly and efficiently
opened,modified, and joined,minimizing the chance of aberrant
joining and chromosomal translocations. Attesting to the effi-
ciency of NHEJ repair, P53 is not activated by DSBs generated
during V(D)J recombination in wild-type mice (Guidos et al.,
1996). In cases of persistent DSBs brought about by defects
during V(D)J recombination, mechanisms exist to either sense
and repair the breaks or eliminate cells with persistent DSBs.
P53 is critical for such cellular responses to DNA damage
(Khanna and Jackson, 2001; vanGent et al., 2001). For example,
P53 is activated in developing thymocytes in mice deficient in
DNA-PKcs because DSBs generated during V(D)J recombina-
tion cannot be repaired by NHEJ (Guidos et al., 1996; Haks
et al., 1999). Because of P53-mediated cell cycle arrest and ap-
optosis, only a small percentage of NHEJmutantmice develop T
cell lymphoma, and then only after a latency period of 6 months
or more (Difilippantonio et al., 2000; Gu et al., 1997; Jhappan
et al., 1997; Li et al., 1998).
Nevertheless, defective V(D)J recombination has been linked
to chromosomal translocations and tumorigenesis (Tycko and
Sklar, 1990; Vanasse et al., 1999). The most convincing and de-
tailed studies have utilized mutant mice that are defective in the
repair of RAG-mediated DSBs, as a result of deletion of a com-
ponent of NHEJ machinery, and cellular responses to persistent
DSBs, as a result of loss of P53 function (Bassing et al., 2002).
P53-deficient mice display grossly normal T cell development
and repertoire but succumb to thymic lymphomas by 6 months
of age, independent of RAG-mediated V(D)J recombination
(Nacht et al., 1996). However, p532/2 NHEJ2 mutant mice rap-
idly develop lethal pro-B cell lymphomas by 10weeks of age (Di-
filippantonio et al., 2000, 2002; Frank et al., 2000; Gao et al.,
2000; Nacht et al., 1996). Most importantly, pro-B cell lympho-
mas harbor RAG-dependent translocations between the IgH
and c-myc through a complex breakage-fusion-bridge (B-F-B)
process (Gladdy et al., 2003; Zhu et al., 2002). These findings
show that, in the absence of P53 andNHEJ repair, RAG-induced
DSBs promote rapid development of B cell lymphomas. How-
ever, given the multiple roles NHEJ factors play in general ge-
nome integrity, DSB repair, and V(D)J recombination, precise
assessment of RAG activity in lymphomagenesis in these
NHEJ mutant models is challenging.
Here, we report the impact of RAG activity on lymphomagen-
esis in the presence of an intact NHEJ pathway in mice. This110study takes advantage of P53-deficient mice whose TCR
b gene enhancer (Eb) is inactivated. In the absence of the Eb,
TCRb rearrangement and transcription are blocked, leading to
arrest of T cell development at the DN stage (Bouvier et al.,
1996; Ryu et al., 2003), where RAG is naturally expressed. We
show that (1) Eb mutation dramatically accelerates the onset
of lethal thymic lymphoma in p532/2mice; (2) the T cell lympho-
mas exhibit RAG-dependent chromosome 12 and 14 transloca-
tions and amplification of the chromosomal region 9A1–A5.3;
and (3) progression of lymphomagenesis goes through the nor-
mal thymocyte development pathway. The unique experimental
attributes of the Eb mutation provide an opportunity to assess
the cytogenetic and carcinogenic consequences of expression
of endogenous RAG that are confined to the physiologically rel-
evant stages of thymocyte development. Our results raise the
fundamental possibility that any genetic aberration leading to
an early lymphocyte block and persistent RAG expression can
act as a procarcinogenic event.
Results
Thymocytes express RAG2 and undergo massive
apoptosis in EbR/R mice
The Eb is a major cis element known to regulate TCRb rear-
rangement and transcription. Its inactivation, either by deletion
or replacement with Gal4 DNA sequences (referred to as Eb2/2
and EbR/R, respectively), in mice results in a severe block of
Db to Jb rearrangement and collapse in thymocyte cellularity
(Bouvier et al., 1996; Mathieu et al., 2000; Ryu et al., 2003). Thy-
mocyte development in EbR/R mice is primarily blocked at the
DN stage (Figure 1A). A significant number of cells progress to
the DP stage, presumably due to selection via TCRgd because
EbR/R TCRd2/2 (referred to as ED) mice display a completely
DN block (Figure 1A). As expected, DN thymocytes of ab lineage
in EbR/R and ED mice were arrested at the CD442CD25+ (DN3)
stage (Figure 1A, lower panel), when TCRb rearrangement nor-
mally occurs. These findings in EbR/Rmice are identical to those
observed in the Eb2/2 mice (Leduc et al., 2000).
To verify the expression of RAG in DN and DP thymocytes
of EbR/R mice, we used mice in which a RAG2-GFP fusion
gene was knocked into the endogenous RAG2 locus (Monroe
et al., 1999). As shown in Figure 1B, most ab lineage thymocytes
from RAG2+/GFP mice were RAG2 positive, as indicated by GFP
expression. Compared to those of RAG2+/GFP mice, DN and/or
DP thymocytes from EbR/R RAG2+/GFP and ED RAG2+/GFP mice
expressed equivalent levels of RAG2.
To examine the fate of EbR/R thymocytes, DN and DP thymo-
cytes from 4- to 6-week-old mice were assayed for apoptosis
by staining with annexin V. Approximately 60% of DN and 80%
of DP thymocytes of EbR/R mice were apoptotic, representing
approximately 9- and 18-fold increases, respectively, over
wild-type counterparts (5%–7%) (Figure 1C). To investigate the
role of P53 in the apoptosis of the EbR/R thymocytes, we gener-
ated EbR/R p532/2 mice (referred to as EP mice). The percent-
ages of apoptotic EP thymocytes were about 24% (DN) and
36% (DP), representing a reduction of approximately 2-fold rela-
tive to those of EbR/R thymocytes (Figure 1C). Nevertheless, the
proportions of apoptotic thymocytes in EP mice were still signif-
icantly higher than those in wild-type or p532/2mice. Together,
these results show that most EbR/R thymocytes express RAG2CANCER CELL FEBRUARY 2006
A R T I C L Eand undergo massive apoptosis by mechanisms that partly in-
volve P53.
The EbR/R mutation accelerates the development
of thymic lymphoma in p532/2 mice
The EbR/R mouse model provides a direct means of assessing
the lymphomagenic potential of RAG expression in the setting
Figure 1. Thymocyte development, RAG2 expression, and apoptosis in EbR/R
mice
A: Comparison of thymocyte phenotypes of wild-type (wt), EbR/R, and EbR/R
TCRd2/2 mice. Thymocytes were stained with antibodies specific for CD4,
CD8, TCRgd, CD44, and CD25. CD4 versus CD8 staining profiles are shown
for total thymocytes (top row). CD44 versus CD25 staining profiles are shown
for TCRgd-negative DN thymocytes (lower row).
B: RAG2 expression in DN and DP thymocytes. One copy of GFP-tagged
RAG2 was bred into wt, EbR/R, and EbR/R TCRd2/2 mice. Thymocytes without
GFP-tagged RAG2 were used as a negative control (shaded areas). TCRgd
thymocytes were excluded from analysis.
C: Effect of the EbR/R mutation on thymocyte apoptosis. Thymocytes from 4-
to 6-week-old wt, p532/2, EbR/R, and EP mice were stained for CD4, CD8,
TCRgd, annexin V, and DAPI. Percentages of annexin+ DAPI2apoptotic cells
were quantified for TCRgd-negative DN and DP thymocytes. Shown are fold
changes in the percentage of apoptotic cells in indicated mice relative to
wt mice. Data are from three independent experiments with at least two
mice per genotype per experiment. Error bars indicate the standard devia-
tion of percentage apoptotic cells within each genotype set.CANCER CELL FEBRUARY 2006of normal DNA DSB repair. As shown in Figure 2A, all Eb+/R
and EbR/R mice remained free of thymic neoplasm over a 12
month observation period. Consistent with previous reports
(Jacks et al., 1994; Nacht et al., 1996), approximately 70% of
p532/2mice succumbed to thymic lymphomaswith amean sur-
vival ofw22weeks. In contrast, 12 of 18 EPmice developed thy-
mic lymphoma with a mean survival of 14 weeks (Figure 2A), as
determined by necropsy, histology (Figure 2B), and flow cytom-
etry (Figures 2C and 2D). Lymphomas arising in EP mice mostly
remain in the thymus and only inefficiently spread to other or-
gans, presumably due to the absence of TCR (Engel and Murre,
2002). The accelerated onset of lethal thymic lymphomas in EP
mice was not a result of differences in genetic background be-
cause both strains were on similar C57BL/6 backgrounds and
EP mice derived from different mating strategies exhibited sim-
ilarly uniform and rapid disease progression. Thus, lymphoma-
genesis is accelerated in p532/2mice in the absence of the Eb.
Progression of lymphomagenesis through DP stage
in EbR/R p532/2 mice
Freshly isolated lymphoma cells from different EP mice ex-
pressed high levels of Thy-1, CD8, variable levels of CD4, but
not B220 (Figure 2D and data not shown), confirming their T
cell identity. Unlike mature CD8 SP thymocytes from wild-type
or p532/2 mice, CD8-positive lymphoblasts from EP mice ex-
pressed high levels of CD24 but very low levels of CD5, CD69,
IL-7Ra, and Qa2 (Figure 2C and data not shown), indicating an
immature developmental stage and a lack of proper positive se-
lection (Bendelac et al., 1992). In support of this interpretation,
CD8+ thymocytes in EP mice did not express TCRb on the cell
surface or within the cell (data not shown).
We next examined the onset and progression of lymphoma
development in EP mice. Through 5–6 weeks of age, EP mice
had identical proportions of DN and DP thymocytes as EbR/R
mice (Figure 2D). By 7 weeks of age, however, some DP thymo-
cytes started to lose CD4 expression and gradually became
CD8 SP. A significant fraction of DP and SP cells were large
and actively cycling, and some were aneuploid (Figure 2D). By
8 weeks of age, over 60% of the thymocytes were CD8 SP.
By 11–17 weeks, mice developed terminal thymic lymphomas
characterized by massive expansion of large, aneuploid CD8
SP cells and sometimes DP cells (Figure 2D), which were readily
propagated in vitro.
A characteristic feature of lymphoma development in EPmice
is an initial increase in the proportion of DP thymocytes followed
by the appearance of DP andCD8 SP tumor cells. To investigate
the requirement for TCRgd-mediated DP thymocyte develop-
ment in lymphomagenesis, we generated EbR/R p532/2
TCRd2/2 (referred to as EPD) mice. Before 4 weeks of age, al-
most all thymocytes in EPDmice were DN (Figure S1 in the Sup-
plemental Data available with this article online), similar to ED
mice. As mice aged, however, DP thymocytes first appeared,
followed by CD8 SP cells. Freshly isolated lymphoma cells
from terminally ill EPDmicewere DP or CD8 SP, cycling, and an-
euploid (Figure S1). Similar to EPmice, themean survival of EPD
mice was 14 weeks. These results suggest that lymphoma de-
velopment in EP and EPD mice is very similar both in terms of
kinetics and the phenotype of the emergent lymphoma cells.
They further suggest that lymphomas develop from the DN pre-
cursors of ab lineage thymocytes and that progression to the DP111
A R T I C L EFigure 2. EbR/R mutation synergizes with P53 deficiency in development of
thymic lymphomas
A: Survival of a cohort of EbR/R, p532/2, EbR/R p532/2, and EbR/R p532/2
RAG22/2 mice was followed over the indicated time period. Numbers of
mice (n) in each group are indicated. A subset of mice, including 6 out of
18 EP mice, 5 out of 18 EPR mice, and 4 out of 15 p532/2mice, died between
3 and 7 weeks of age due to causes other than thymic lymphoma and were
therefore excluded from the survival plot.
B: Hemoxylin and eosin stain of thymus sections of a wt and a terminally ill
EbR/R p532/2 mouse (14 weeks). Magnification 403. Note that thymic112stage, by a mechanism independent of TCRgd, is associated
with lymphomagenesis.
RAG2 is expressed during the course
of lymphomagenesis and in resulting lymphoma lines
Based on the effect of the Ebmutation on T cell development as
well as the critical role of P53 in mediating cellular responses to
DSBs, we investigated the role of RAG activity in lymphomagen-
esis in EP mice. To begin to test this mechanism, we followed
RAG2 expression during the course of lymphomagenesis by in-
troducing the GFP-tagged RAG2 allele into EPDmice or their lit-
termates (EbR/R p53+/2 TCRd2/2). As with EP or EPD mice, de-
velopment of thymic lymphomas in EPD RAG2+/GFP mice
exhibited a similar kinetics and phenotypic progression. Thus,
at 4 weeks of age, thymocytes from EPD RAG2+/GFP mice
were all DN (Figure 3A). By 8 weeks of age, DP and CD8 SP lym-
phoblasts appeared, and by 14 weeks of age, most thymocytes
were DP or CD8 SP in terminally ill mice (Figure 3A). Importantly,
DP thymocytes from EPD RAG2+/GFP mice at both the interme-
diate (8 week) and terminal stage (14 week) expressed RAG2
(Figure 3B). Similarly, RAG2 expressionwas detected in DP cells
during lymphomagenesis in EP mice and in lymphoma cells that
had been cultured for 2 weeks (data not shown). In addition,
RAG2 transcripts were readily detected by Northern blotting in
all three randomly selected EP lymphoma lines that had been
cultured for months, whereas no expression was detected in
a p532/2 lymphoma line (Figure 3C). Together, these results
suggest that RAG is expressed during lymphomagenesis and
in resulting lymphoma cells, supporting the possibility that
RAG-induced aberrant cleavages may have contributed to the
accelerated lymphoma development in EP mice.
Both normal and aberrant RAG-mediated
rearrangements occur in EbR/R p532/2 lymphomas
Next, we examined RAG activity by assaying for the presence of
rearrangements at antigen receptor loci and other genomic loci
in EP lymphomas. Genomic DNA from both p532/2 and EP lym-
phomas and from thymocytes of wild-type andmutantmice was
analyzed by Southern blotting. Hybridization with probes from
Db1–Jb1, Db2–Jb2, and Cb1 regions (Figure 4A) revealed that
the Db1–Jb1 region and to a lesser extent the Db2–Jb2 region
were rearranged in wild-type thymocytes but not in EbR/R, EP,
and RAG22/2 thymocytes (Figures 4B–4D). Similarly, the Db1–
Jb1 region was rearranged in two of the three p532/2 lymphoma
lines, consistent with normal T cell development in p532/2mice.
In contrast, both Db1–Jb1 and Db2–Jb2 regions were in germ-
line configuration in all seven EP lymphoma lines (Figures 4B–
4D). These results were further confirmed by PCR amplification
cytoarchitecture of EP mice is replaced with monotonous fields of large,
highly mitotic lymphoblasts.
C: Comparison of surface phenotype of CD8 SP thymocytes among wt,
p532/2, and EP mice. Thymocytes of 6- to 8-week-old mice were stained
for CD4, CD8, and TCRgd, as well as CD5, CD24, CD69, or IL-7Ra. Shown is ex-
pression of various markers for TCRgd2 CD8 SP thymocytes.
D: Progression of lymphomagenesis in EbR/R p532/2 mice. Thymocytes from
EP mice at indicated ages were stained for CD4, CD8, TCRgd, and propi-
dium iodide (PI). Left panel: CD4 versus CD8 staining profiles of TCRgd2 thy-
mocytes (PI2); percentages of cells in each quadrant are shown. Middle
panel: cell size (FSC, forward scatter) of TCRgd2 DP and CD8 SP cells. Right
panel: DNA content of TCRgd2DP and CD8 SP cells. Most of the thymocytes
(>95%) in EbR/R mice at the indicated ages were either DN or DP as shown in
Figure 1A.CANCER CELL FEBRUARY 2006
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Jb1.5 gene segments in the seven lymphomas (data not shown).
Thus, the gross translocation of the TCRb locus is not a contrib-
uting factor to the observed acceleration of lymphoma develop-
ment in EP mice.
The same blot was hybridized with a Ja49-48 probe from
the 50 end of the Ja region of the TCRa locus. As expected,
Figure 3. RAG2 is expressed during the course of lymphomagenesis and in
lymphoma lines
A and B: Tracking RAG2 expression during lymphomagenesis. GFP-tagged
RAG2 was introduced into EPD mice and littermate controls (with one
wild-type p53 allele). At indicated ages, thymocytes were assayed for
CD4, CD8, and GFP (RAG2) expression. CD4 versus CD8 staining profiles
are shown for total thymocytes (A), and GFP (RAG2) expression is shown
for DP thymocytes of 8-week-old and terminal 14-week-old mice (B). DP thy-
mocytes from wild-type mice were used as a negative control (shaded
areas).
C: Northern blotting analysis of RAG2 transcripts in total RNA from a p532/2
(P99) and EP (EP70, EP173, and EP175) thymic lymphoma lines. RNA from
wild-type thymus is included as a positive control. Hybridization with
a GAPDH probe is used to normalize the relative level of RNA loading in dif-
ferent lanes.CANCER CELL FEBRUARY 2006Figure 4. RAG-mediated rearrangements at the TCRa and IgH loci in EbR/R
p532/2 lymphomas
A: Schematic diagrams of the TCRb, TCRa, and IgH loci and the position of
probes used.
B–F: Southern blotting analyses of rearrangements at the TCRb, TCRa, and
IgH loci in thymocytes and thymic lymphomas. Genomic DNA was digested
with EcoR1, separated on an agarose gel, transferred to a filter, and hybrid-
ized with various probes successively (from top to bottom) after removal of
the previous probe. Thymic lymphomas from EP mice are labeled as EP54,
etc., and those from p532/2 mice are labeled as P77, etc. The rest of the
DNA samples were from thymocytes of indicated mice. Two EP mice, one
at 4 weeks of age and the other at 8 weeks of age, were used. Arrows indi-
cate germline fragments.
G: Sequences of IgH rearrangements from thymic lymphomas EP70 and
EP116. IgH rearrangements were amplified by digestion-circularization
PCR and then cloned and sequenced. Specific gene segments used in re-
arrangements are identified. N nucleotides are indicated, and possible P
nucleotides are underlined.113
A R T I C L Ea germline fragment was detected in thymocyte DNA from
RAG22/2 mice (Figure 4E). In contrast, the Ja49-48-hybridizing
signal was greatly reduced in thymocyte DNA from wild-type
mice, indicating deletion of the Ja region by rearrangement.
The Ja49-48-hybridizing signal was also absent or greatly re-
duced in all EP lymphomas and the three p532/2 lymphomas,
indicating TCRa rearrangements. Notably, the Ja49-48-hybrid-
izing signal was abundant in thymocyte DNA from both Eb2/2
and EbR/R mice but greatly diminished in that from both 4- and
8-week-old EP mice. The lack of TCRa rearrangements in EbR/R
mice could reflect the rapid apoptosis of these cells whereas
EP thymocytes have a prolonged survival and an opportunity
to undergo RAG-mediated rearrangements.
To investigate the presence of RAG-mediated aberrant rear-
rangements in EP lymphomas, we assayed for IgH JH rearrange-
ments using a probe spanning the intronic enhancer (Em; Fig-
ure 4A). As expected, the JH region was in germline
configuration in wild-type,RAG22/2, EbR/R, and EP thymocytes,
and in p532/2 thymic lymphomas. In contrast, four of the seven
EP lymphoma lines had undergone JH rearrangements, as indi-
cated by the presence of at least one nongermline JH fragment
(Figure 4F). In two of the four EP lymphoma lines (EP54 and
EP116), the germline JH fragment was completely absent, indi-
cating a complete JH rearrangement on both alleles. Cloning
and sequencing of some of these Em-hybridizing nongermline
fragments from lymphomas EP70 and EP116 revealed that all
four independent clones were derived from complete VH-D-JH
rearrangements (Figure 4G). In particular, the two VH-D-JH rear-
rangements from lymphoma EP116 had identical D-JH junc-
tional sequences but different VH to DJH rearrangements. Given
that the complete VH-D-JH rearrangements are extremely rare in
T cells in wild-type mice, these results support the view that
RAG expression in EP thymocytes can result in aberrant rear-
rangements.
Further evidence for RAG-mediated aberrant rearrangements
in EP lymphomas was obtained by assaying for internal deletion
at the Bcl11b locus, which contains cryptic RSS and is accessi-
ble to RAG in DN thymocytes (Sakata et al., 2004). PCR prod-
ucts of approximately the correct size were detected in all six
EP lymphoma lines but not in two p532/2 lymphoma lines
(Figure 5B). The PCR products were also absent in three lym-
phoma lines from EbR/R p532/2 RAG22/2 (referred to as EPR)
mice, indicating a requirement of RAG2 for the internal deletion.
Furthermore, sequences of PCR products from all seven EP
lymphoma lines displayed hallmarks of RAG-mediated rear-
rangements at the joints, including nucleotide deletions, non-
templated nucleotide additions (N), and palindromic (P) se-
quences. However, by Southern blotting, a large proportion of
Bcl11b locus remained in the germline configuration in EP lym-
phomas (data not shown), suggesting that Bcl11b deletions are
secondary to lymphomagenesis and reflect ongoing RAG activ-
ity in lymphoma lines. Taken together, these results strongly
suggest that RAG can aberrantly cleave both antigen receptor
loci that are normally inaccessible in T cells and nonantigen re-
ceptor loci in EP lymphomas.
EbR/R p532/2 lymphomas exhibit RAG-dependent
recurrent chromosomal alterations
We next examined chromosomal alterations in EP lymphomas
by spectral karyotyping (SKY). As shown in Figure 6 and
Table 1, p532/2 lymphomas displayed extensive numerical114chromosomal aberrations, with infrequent nonclonal transloca-
tions, as previously reported (Difilippantonio et al., 2002; Liao
et al., 1998). While EP lymphomas resembled p532/2 lympho-
mas (exhibiting extensive numerical chromosomal aberrations),
distinct karyotypic events were evident, including frequent
translocations involving chromosomes 9, 12, or 14. Among 52
translocations detected in 69 spreads, 47 translocations in-
volved chromosomes 9, 12, or 14, a frequency significantly
higher than expected from a random event (p < 0.0001). Simi-
larly, EPD lymphomas harbored frequent chromosome 9 trans-
locations (12 out of 16 in 26 spreads). Chromosomes 12 and 14
harbor the IgH and TCRa loci, respectively, raising the possibility
that these translocations are initiated by RAG-mediated cleav-
ages at those loci. Consistent with this possibility, lymphomas
from EPRmice that were deficient inRAG2 had no chromosome
9, 12, or 14 translocations among 32metaphase spreads exam-
ined in three independent lymphoma lines. Even among 46
spreads examined in five p532/2 lymphoma lines, only 5 of 28
translocations involved chromosomes 9, 12, or 14, a frequency
not significantly different from that expected from a random
event (p = 0.23). Compared to those in EPR or p532/2 lympho-
mas, the frequency of chromosome 9, 12, or 14 translocations
was significantly higher in EP lymphomas (p < 0.0001 for both
comparisons). There was no statistical difference in the fre-
quency of chromosome 9, 12, or 14 translocations between
EPR and p532/2 lymphomas (p = 0.31). Together, these results
suggest that RAG activity is required for the generation of chro-
mosomal aberrations characteristic of EP lymphomas.
To examine genomic aberrations in EP lymphomas in greater
detail, we performed array-based comparative genomic
Figure 5. RAG-mediated internal deletion at the Bcl11b locus in EbR/R p532/2
lymphomas
A: Schematic diagrams of the PCR assay for Bcl11b internal deletion. PCR
amplification of Bcl11b is only possible upon internal deletion of exons 2
and 3 as the primers are 65 kb apart. Open boxes, exons; gray triangles,
cryptic RSS; and arrows, PCR primers.
B: Ethidium bromide staining of PCR products amplified from independently
derived p532/2, EbR/R p532/2, and EbR/R p532/2 RAG22/2 lymphoma lines.
Arrow indicates the correct product.
C: Junctional sequences of Bcl11b internal deletion products. PCR products
from B were cloned and sequenced and compared to germline se-
quences. Nucleotide deletions and P and N nucleotides are indicated.
Cryptic RAG recognition sites in the germline Bcl11b locus are underlined.CANCER CELL FEBRUARY 2006
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p532/2 lymphomas
A: Examples of spectral images of thymic lym-
phomas from p532/2 (P99, left panel) and EbR/R
p532/2 (EP173, right panel) mice. The white ar-
rows indicate two t(12;16) translocations ob-
served in a EP173 metaphase spread. The right
panel shows the classified (left) and DAPI (right)
images of one of the t(12;16) translocations.
B: SKY analyses of an EbR/R p532/2 TCRd2/2 lym-
phoma (EDP1). Spectral all-chromosome paint
(left panel) and chromosome 9-specific paint
(middle panel) images are shown. Tricentric
chromosome 9 is boxed, and asterisk indicates
a chromosome 9 fragment. In the right panel,
spectral, DAPI, and classified images of the tri-
centric chromosome 9 are indicated. C indi-
cates centromere, which does not stain.hybridization (array CGH) analyses on six EP and three p532/2
lymphomas. Representative ideograms are shown in
Figure 7A, with the rest presented in Figures S2 and S3 and Ta-
ble S1.Whole chromosome gains of 4, 14, and 15were common
in both types of lymphomas, suggesting that P53 deficiency
may nonrandomly lead to the duplication of these chromo-
somes. Lymphoma line EP175, which harbored a 14:5 translo-
cation (Table 1), exhibited a mosaic (partial) gain of the chromo-
some 14 but not chromosome 5. Lymphoma lines with
chromosome 12 translocations (EP116, EP173, and EP70) did
not exhibit amplification of chromosome 12, suggesting that
the translocations are not associated with amplifications.
Chromosome 9 alterations were seen in all six independently
derived EP lymphoma lines (Figure 7B, Figure S2, and Table S1).
While whole chromosome gain (EP173) and a partial loss
(EP175) were noted, the most frequent alteration involved mo-
saic gains of various parts of the 9A1–A5.3 region (EP116,
EP175, EP23, EP70, and EP88). Lymphoma line EP70 harbored
a single amplicon, encompassing up to a 550 kb region that in-
cludes the Ets-1 locus (Figure 7B). Southern blotting analysis
confirmed that the Ets-1 is amplified (data not shown). Other
EP lymphoma lines harbored much larger amplicons (on the or-
der of megabases), with breakpoints at various locations within
the 9A1–A5.3 region. Notably, amplification breakpoints often
fell near genes commonly involved in lymphoma pathogenesis
in mice and humans, including Ets-1 (EP70, EP88, EP116) (Oi-
kawa and Yamada, 2003), Mll (EP23, EP88, EP175) (Greaves
and Wiemels, 2003; Tanaka et al., 2001), and Atm (EP88,
EP116) (Stilgenbauer et al., 1997).
Furthermore, we investigated the nature of mosaic amplifica-
tion of chromosome 9 by SKY analysis using a chromosome 9-
specific paint. As shown in Figure 6B, lymphoma line EPD1 had
two normal copies of chromosome 9 as well as a tricentric chro-
mosome 9 with amplifications. Interestingly, a fragment of chro-
mosome 9 was visible in one SKY image, suggesting thatCANCER CELL FEBRUARY 2006chromosome 9 is prone to breakage. Together, these findings
suggest that recurrent chromosome 9 alterations are RAG de-
pendent and may be a significant contributing factor to the ac-
celerated lymphomagenesis in EP mice.
RAG2 is required for the accelerated lymphomagenesis
in EbR/R p532/2 mice
To further determine the requirement of RAG activity in the ac-
celerated lymphoma development in EP mice, we monitored
lymphoma-free survival of EbR/R p532/2 RAG22/2 (EPR) mice.
Five out of 18 EPR mice died before 7 weeks of age, including
one with teratocarcinoma, one with B cell lymphoma, and three
with unknown cause. The rest of EPR mice succumbed to thy-
mic lymphomas between 11 to 23 weeks of age with an average
survival of 18 weeks (Figure 2A). Compared to EP mice, on
average, EPR mice lived significantly longer (p < 0.0001), how-
ever, they still succumbed to thymic lymphoma at younger
ages than p532/2mice (p = 0.0063). Nevertheless, EPR lympho-
mas did not exhibit the distinct chromosomal alterations charac-
teristic of EP lymphomas, but rather resembled p532/2 lympho-
mas in karyotypes (Figure 6 and Table 1). Together, these
findings suggest that RAG activity is a critical contributing factor
to the accelerated lymphomagenesis in EP mice.
Discussion
RAG activity synergizes with deficient DNA damage
responses in lymphomagenesis
In this report, we present several lines of evidence to support
a model in which stalled thymocyte development as an indirect
consequence of Eb inactivation results in RAG expression and
inappropriate DNA cleavages that synergize with a defective
DNAdamage response to provoke lymphomagenesis. First, thy-
mocyte development in the EbR/Rmice is blocked at stages that
normally express RAG and are prone to apoptosis. Second,115
A R T I C L ETable 1. Summary of SKY analyses
Cell lines Genotype Metaphase examined Range (average) Translocations Frequency
















EP173 EbR/R p532/2 20 43–92 (57) t(12;16) 20/20
EP175 EbR/R p532/2 16 46–64 (56) t(14;5) reciprocal 2/16
t(6;16) 1/16
t(5;9) 1/6
EPD1 EbR/R p532/2 TCRd2/2 14 42–47 (45) t(9:9:9) 3/14
t(9:X) 3/14
EPD16 EbR/R p532/2 TCRd2/2 6 42–50 (46) t(4:16) 3/6
t(3;14) 1/6
t(9;10) 1/6
EPD112 EbR/R p532/2 TCRd2/2 6 40–43 (41) t(9;16) 5/6
P99 p532/2 10 40–49 (45) t(15;16) 1/10
t(1;11) 1/10
t(X;8) 1/10







* p532/2 5 48–50 (49) none
* p532/2 10 39–60 (42) t(15;15) 8/10
* p532/2 10 39 (39) t(2;19) 5/10
EPR2 EbR/R p532/2 RAG22/2 11 37–51 (44) none
EPR51 EbR/R p532/2 RAG22/2 11 46–52 (49) t(10;11) reciprocal 8/11
EPR68 EbR/R p532/2 RAG22/2 10 38–49 (43) none
Various lymphomas were analyzed by SKY. Shown are numbers of metaphases examined and average numbers of chromosomes, as well as the range for
each lymphoma line, chromosome translocations, and chromosome frequencies. t, translocation (the chromosome donating the centromere is listed first);
Rb, Robertsonian translocation. *Data are from study by Liao et al. (1998).inactivation of P53 in the EbR/R mice resulted in a partial rescue
of thymocytes from apoptosis and accelerated onset of fatal
thymic lymphoma as compared to p532/2 mice. Third, RAG2
protein was detected during lymphomagenesis, and RAG2 tran-
script was detected in the resultant lymphoma lines. Fourth,
Southern blotting and PCR analyses revealed RAG-mediated
rearrangements at TCRa, IgH, and Bcl11b loci in EP lympho-
mas, suggesting RAG cleavages in these regions at some point
in the life of the transformed clones. Fifth, most EP lymphomas
harbor translocations that frequently involve chromosomes 12
or 14, which possess RAG target sites across the resident IgH
and TCRa loci, respectively. These translocations are RAG de-
pendent, as they were absent in lymphomas from EPR mice. Fi-
nally, genetic deletion of RAG2 allowed EP mice to survive an
average of 18weeks compared to 14weekswhen RAG2 is pres-
ent, although the average survival of p532/2micewas still longer
(22 weeks). The lack of complete rescue could be due to other
effects of the Eb mutation, including difference in thymocyte116development or frequency of precursor tumor cells between
p532/2 mice and EPR mice (see below). Together, these find-
ings implicate RAG activity as an important factor in synergizing
with P53 deficiency in lymphomagenesis.
Our findings suggest a general model in which any condition
that allows RAG expression would accelerate tumorigenesis in
a DNA damage checkpoint-deficient background. This model
is consistent with previous findings implicating inappropriate
RAG-mediated DSBs at antigen receptor loci and other cryptic
RSS sites throughout the genome in lymphomagenesis (Lewis
et al., 1997; Marculescu et al., 2002; Raghavan et al., 2004; Sa-
kata et al., 2004). Importantly, our findings extend the range of
molecular aberrations that can drive the development of lym-
phomas. During lymphocyte development, RAG expression is
activated at distinct developmental stages and is shut off by
feedback inhibition of the functionally assembled gene prod-
ucts. Manymutations block lymphocyte development at a stage
where RAG is naturally expressed. For example, mutations ofCANCER CELL FEBRUARY 2006
A R T I C L EFigure 7. Array CGH analyses of p532/2 and EbR/R p532/2 lymphomas
A: Representative ideograms of one EP lymphoma (EP116) and one p532/2 lymphoma (P99). Chromosomes are listed in numerical order from left to right.
Points above zero on y axis represent amplifications, and those below zero indicate deletions relative to the diploid control. The red line running through
the individual points represents the average values. X chromosome profiles should be discounted, as some lymphomas were derived from male mice and
the reference DNA was from a wild-type female mouse.
B: Overlay of chromosome 9A1–A5.3 region and array CGH signal of the indicated EP lymphomas and p532/2 lymphomas. Arrows indicate amplification of
regions corresponding to Ets-1, Mll, and Atm loci.TCRb, CD3e, or NHEJ genes all interfere with pre-TCR expres-
sion and therefore block T cell development at the DN3 stage
where RAG is expressed. According to our model, all these mu-
tations would be expected to accelerate development of thymic
lymphomas in p532/2mice. Consistent with this notion, p532/2
NHEJ2 mice rapidly develop fatal pro-B cell lymphomas due to
oncogenic translocations involving IgH and c-myc (Bassing
et al., 2002).CANCER CELL FEBRUARY 2006Contribution of the EbR/R mutation to lymphomagenesis
by RAG-independent mechanisms
It should be noted that the EbR/Rmutation might also contribute
to lymphomagenesis through mechanisms independent of its
effect on RAG activity. Consistent with this notion, RAG2 defi-
ciency did not completely extend the lymphoma-free survival
time of EP mice to that observed for p532/2 mice. Loss of the
Eb function and consequently the inability to express pre-TCR117
A R T I C L Eor TCR severely perturbs thymocyte differentiation, prolifera-
tion, and survival that can in several ways predispose to trans-
formation. First, the DN3 stage at which most EbR/R thymocytes
are blocked has been shown to exhibit heightened kinase activ-
ity, lower signaling thresholds, and proclivity to transformation
(Haks et al., 2003). Second, DN to DP progression in p532/2
mice without proper pre-TCR signaling can lead to cellular
transformation (Haks et al., 1999), even in the absence of RAG
(Jiang et al., 1996). Consistently, we found that lymphomagene-
sis in EP mice requires DN to DP progression, and the transition
is RAG independent. Third, EbR/R thymocytes exhibit signifi-
cantly elevated levels of apoptosis relative to wild-type or
p532/2 thymocytes, and only a portion of this apoptosis is pre-
vented by the loss of P53, indicating that EbR/R thymocytes ex-
perience other stresses that may cooperate with the P53 defi-
ciency in lymphomagenesis. Nevertheless, given that the
lymphomas in EP, EPR, and EPD mice all exhibit CD4+CD8+
or CD8+ phenotypes, the precise role of arrested T cell develop-
ment in the observed lymphomagenesis remains to be deter-
mined.
Characteristic chromosome translocations
and amplifications in accelerated lymphomagenesis
of EP mice
We found frequent IgH and TCRa rearrangements, and corre-
spondingly chromosome 12 and 14 translocations, in EP thymic
lymphomas. The most frequent chromosomal alterations in EP
lymphomas are mosaic gains of the 9A1–A5.3 region. We also
noted frequent involvement of chromosome 9 in translocations
with chromosomes 12 or 14 as well as with itself (tricentric). Al-
terations of the 9A1–A5.3 region are also frequently observed in
H2AX2/2 p532/2 thymic lymphomas (Celeste et al., 2003) and
p532/2 NHEJ2 pro-B lymphomas (Zhu et al., 2002). Several
genes known to be involved in DNA damage responses and ge-
nome integrity, such asAtm (Stilgenbauer et al., 1997) andH2AX
(Bassing et al., 2003; Celeste et al., 2003), and oncogenesis,
such as Mll (Greaves and Wiemels, 2003; Tanaka et al., 2001)
and Ets-1 (Oikawa and Yamada, 2003), are located within this
region and fall within amplification breakpoint regions in EP lym-
phomas. Notably, the syntenic 11q22–25 region in humans is
also frequently deleted, rearranged, or amplified in many hema-
tological malignancies (Greaves and Wiemels, 2003) and is as-
sociated with a worsened prognosis (Monni and Knuutila,
2001). Similarly, translocations involving the IgH and TCRa loci
are frequently found in human lymphomas and leukemias
(Tycko and Sklar, 1990; Vanasse et al., 1999). It is likely that
RAG-induced alterations to the chromosome region 9A1–A5.3
or chromosome 12 and 14 translocations provide a selective ad-
vantage to emergent EP clones, either through oncogene acti-
vation or inactivation of genes required for genome stability
and DNA repair.
Studies inmice deficient in both P53 andNHEJ have identified
IgH/c-myc translocation involving a complex B-F-B mechanism
as the critical event for the development of pro-B cell lympho-
mas (Zhu et al., 2002). Although we observed chromosome 9
fragmentation and tricentric formation, we did not frequently ob-
serve the B-F-B intermediates or products. This is probably
because most of RAG-mediated cleavages are repaired in
EP thymocytes, whereas in p532/2 NHEJ2 mice, breaks
generated during V(D)J recombination cannot be repaired by
the NHEJ pathway but have to exert alternative, error-prone118microhomology-directed repair that could initiate the B-F-B
cycle. Consistently, P53 activationwas observed in primary lym-
phoid organs of NHEJ2 mice (Danska et al., 1996), but not in
wild-type orEbR/Rmice (data not shown). The differences under-
score the distinctions in lymphomagenesis between the EP
model and p532/2 NHEJ2 model.
Cellular pathways of thymic lymphomagenesis
One of the striking feature of lymphomagenesis in EP, EPD, and
EPR mice is that tumor cells were DP or CD8 SP and that the
emergence of these tumor cell populations was preceded by
the development of DP cells. As normal thymocyte development
progresses from DN to DP and then to SP stages, these findings
raise the question as to whether the normal development path-
way is coopted by lymphomagenesis in the mutant mice. While
the preexistence of DP cells in EPmice allows the possibility that
lymphomagenesis occurs within this cell population, this cannot
be the case for EPD or EPRmice, whose thymus is initially com-
posed solely of DN cells. Further supporting this hypothesis, in-
troduction of p532/2 mutation into RAG22/2 or CD3g2/2 mice
promotes DN to DP thymocyte differentiation before the devel-
opment of DP or CD8 SP thymic lymphomas (Haks et al., 1999;
Jiang et al., 1996; Nacht and Jacks, 1998). Enforced DN to DP
progression by introduction of a TCR transgene in p532/2
RAG12/2mice also accelerates development of thymic lympho-
mas (Liao et al., 1998). One of the key events that occur during
DN to DP differentiation is cell proliferation. It is possible that this
proliferation is also required for the outgrowth of transformed
clones. Whether transformation takes place in DN cells, which
then differentiate into DP stages, or whether the process of
DN to DP transition is involved in the transformation events re-
mains to be determined.
Experimental procedures
Mice and genotyping
EbR/R p532/2mice were generated by mating EbR/Rwith p532/2, followed by
mating of F1 heterozygous siblings. Due to their rapid development of thymic
lymphoma, EP mice were maintained and generated by EbR/R p53+/2 mat-
ings. To generate EbR/R p532/2 TCRd2/2 mutants, TCRd2/2 mice (Jackson
Laboratory, Bar Harbor, ME) were crossed to EbR/R p53+/2 mice. The Eb
and TCRd mutant alleles were bred to homozygosity, while p53 alleles
were maintained in a heterozygous state for matings. EbR/R p532/2
RAG22/2 mice were generated and maintained by mating EbR/R p53+/2 to
RAG22/2 mice. Genotyping of EbR/R and p532/2 was performed by PCR of
genomic tail DNA (Jacks et al., 1994; Ryu et al., 2003). Genotyping of
TCRd2/2mice was done following protocols provided by the Jackson Labo-
ratory. The primers for RAG2 genotyping were 50-TCTCCAGAACTTCAG
GATG and 50-AGCCTGCTTATTGTCTCCTG for wild-type allele, and 50-
AGCCTGCTTATTGTCTCCTG and 50-GGCACCGGACAGGTCGGTCTTGAC
for mutant allele. All experiments with mice were performed in accordance
with the regulations of the MIT Committee on Animal Care (Protocol 0304-
021-07).
Flow cytometry
Thymocytes (1–10 3 106) were suspended in FACS buffer (0.1% FCS plus
0.02% sodium azide) and incubated with the indicated antibodies on ice
for 30 min, followed by two washes. Data were collected on a FACSCalibur
(Becton Dickinson) and analyzed with CellQuest software. All antibodies
were purchased fromPharmingen (SanDiego, CA). For analysis of apoptosis,
thymocytes were first incubated with a cocktail of CD4-APC, CD8-Cy5.5,
and TCRgd-PE antibodies. The cells were then resuspended in 100 ml an-
nexin binding buffer (10 mM HEPES/NaOH [pH 7.4], 140 mM NaCl, 2.4 mM
CaCl) supplemented with 5 ml of annexin IV-FITC and 2.5 ml of 100 mg/ml
DAPI (Pierce). A total of 1–1.5 3 106 events were collected on a MoFlo3CANCER CELL FEBRUARY 2006
A R T I C L E(Cytomation), and the data were analyzed using Summit software. For cell
cycle analyses, thymocytes were stained with FITC-conjugated CD4 and
CD8 and then permeabilized with Saponin buffer (0.1% Saponin, 1% BSA,
0.02% sodium azide in PBS). The cell pellet was resuspended in Saponin
buffer containing 200 mg/ml PI and 50 mg/ml RNaseA (Sigma), followed by in-
cubation at 15 min at 4ºC.
Southern and Northern blotting and PCR
Genomic DNA isolation and Southern blotting were performed as described
(Ryu et al., 2003). The Ja49-48 intron probe was amplified by PCR with
primers 50-GTAAGTGTGAGGCTATCTAACC and 50-CATTAGTAAGCACT
TATTTCAGG. Db1–Jb1, Db2–Jb2, and Cb1 probes were as described
(Whitehurst et al., 1999). All probes were labeled by random priming with
32P-dCTP. For Northern analysis, 10 mg of total RNA was fractionated on
a 1% formaldehyde agarose gel and transferred to Zeta-probe membrane
(Bio-Rad). The membrane was sequentially hybridized with 32P-labeled
RAG2 and GAPDH cDNA probes. Standard nested PCR to amplify internal
Bcl11b deletions was performed as described (Sakata et al., 2004). All
PCR products were cloned, and five clones originating from each cell line
were sequenced. Digestion-circularization PCRwas used to clone the Em-hy-
bridizing JH fragments from thymic lymphomas. Genomic DNA was digested
with EcoRI, diluted, and ligated. Circularized DNAwas then used as template
for the primary PCR amplification using the primers 50-TTGAGCAATGTT
GAGTTGAGTC and 50-CTGAATAGGGTATGAGAGAGAGCCT. Then, 5 ml of
the primary PCR mixture was subjected to the secondary PCR using the
primers 50-GATGGCCGATCAGAACCGGAACA and 50-CCCATTCCTCGGT
TAAACTTTAAG. PCR products were cloned and sequenced.
SKY and array CGH
Metaphase chromosomes were prepared from thymic lymphoma lines at
early passage numbers (1–3). Cells were incubated in 0.1 mg/ml Colcemid
for 30–60 min and then incubated in 75 mM KCl. Chromosomes were subse-
quently fixed in 3:1 methanol:acetic acid and dropped onto glass slides.
Metaphase spreads were incubated with mouse SkyPaint kit probe (Applied
Spectral Imaging, Carlsbad, CA) followed by counterstain with DAPI. Raw
spectral images were visualized by assigning red, green, and blue colors to
specific spectral ranges. Chromosomes were identified using SKY View soft-
ware (Applied Spectral Imaging). Chromosome aberrations were defined us-
ing the nomenclature rules from theCommittee on Standard Genetic Nomen-
clature for Mice. Six to twenty metaphases were analyzed for each
lymphoma line. Statistical analysis was performed by c2 test, and p value
was determined by Monte Carlo simulation with 107 random iterations. For
array CGH analyses, DpnII-digested genomic DNA from primary EbR/R
p532/2 or p532/2 thymic lymphomas were used for labeling reactions and
hybridized to the Mouse Development Oligo Microarray (G4121A, Agilent
Technologies, Palo Alto, CA). Wild-type thymus genomic DNA was used as
control. Data were assembled and analyzed using CGH Analytics software
(Agilent Technologies).
Supplemental data
The Supplemental Data include three supplemental figures and one supple-
mental table and can be found with this article online at http://www.
cancercell.org/cgi/content/full/9/2/109/DC1/.
Acknowledgments
We thank Dr. Tyler Jacks for p532/2 mice, Drs. Herman N. Eisen and Tania
Baker for manuscript review, and members of the Chen laboratory for helpful
discussions. This work was supported in part by grants AI40416 and
CA100875 from the National Institutes of Health and David Koch Research
Fund (to J.C.), a Cancer Center Core Grant (to Tyler Jacks), a grant from Ko-
rea Science and Engineering Foundation (R01-2004-000-10047-0 to C.J.R.),
and a grant from the Nano-Bio Research and Development Program of the
Ministry of Science and Technology, Korea (TNM0200512 to H.J.H.). S.C.
is supported by the Ellison Medical Foundation, NIH grant AG01019, and
a Belfer Cancer Core grant to the DFCI. R.A.D. is an American Cancer Society
Research Professor and an Ellison Foundation Senior Scholar and is sup-
ported by grants from the NIH and ACS. B.B.H. was partly supported by
a Postdoctoral Fellowship from the American Cancer Society (PF0122801),
and A.L. was partly supported by a Research Fellowship from the DeutscheCANCER CELL FEBRUARY 2006Forschungsgemeinschaft (LU 841/2-1). Array CGH profiles were performed
at the Arthur and Rochelle Belfer Cancer Genomic Center at the Dana-Farber
Cancer Institute.
Received: July 14, 2005
Revised: October 12, 2005
Accepted: January 9, 2006
Published: February 13, 2006
References
Bassing, C.H., Swat, W., and Alt, F.W. (2002). The mechanism and regulation
of chromosomal V(D)J recombination. Cell Suppl. 109, S45–S55.
Bassing, C.H., Suh, H., Ferguson, D.O., Chua, K.F., Manis, J., Eckersdorff,
M., Gleason, M., Bronson, R., Lee, C., and Alt, F.W. (2003). Histone H2AX:
A dosage-dependent suppressor of oncogenic translocations and tumors.
Cell 114, 359–370.
Bendelac, A., Matzinger, P., Seder, R.A., Paul, W.E., and Schwartz, R.H.
(1992). Activation events during thymic selection. J. Exp. Med. 175, 731–742.
Bouvier, G., Watrin, F., Naspetti, M., Verthuy, C., Naquet, P., and Ferrier, P.
(1996). Deletion of the mouse T-cell receptor b gene enhancer blocks ab T-
cell development. Proc. Natl. Acad. Sci. USA 93, 7877–7881.
Celeste, A., Difilippantonio, S., Difilippantonio,M.J., Fernandez-Capetillo, O.,
Pilch, D.R., Sedelnikova, O.A., Eckhaus, M., Ried, T., Bonner, W.M., and
Nussenzweig, A. (2003). H2AX haploinsufficiency modifies genomic stability
and tumor susceptibility. Cell 114, 371–383.
Chu, G. (1997). Double strand break repair. J. Biol. Chem. 272, 24097–24100.
Danska, J.S., Holland, D.P., Mariathasan, S., Williams, K.M., and Guidos,
C.J. (1996). Biochemical and genetic defects in the DNA-dependent protein
kinase in murine scid lymphocytes. Mol. Cell. Biol. 16, 5507–5517.
Difilippantonio, M.J., Zhu, J., Chen, H.T., Meffre, E., Nussenzweig, M.C.,
Max, E.E., Ried, T., and Nussenzweig, A. (2000). DNA repair protein Ku80
suppresses chromosomal aberrations and malignant transformation. Nature
404, 510–514.
Difilippantonio, M.J., Petersen, S., Chen, H.T., Johnson, R., Jasin, M., Ka-
naar, R., Ried, T., and Nussenzweig, A. (2002). Evidence for replicative repair
of DNA double-strand breaks leading to oncogenic translocation and gene
amplification. J. Exp. Med. 196, 469–480.
Dudley, E.C., Petrie, H.T., Shah, L.M., Owen, M.J., and Hayday, A.C. (1994).
T cell receptor b chain gene rearrangement and selection during thymocyte
development in adult mice. Immunity 1, 83–93.
Engel, I., andMurre, C. (2002). Disruption of pre-TCR expression accelerates
lymphomagenesis in E2A-deficient mice. Proc. Natl. Acad. Sci. USA 99,
11322–11327.
Frank, K.M., Sharpless, N.E., Gao, Y., Sekiguchi, J.M., Ferguson, D.O., Zhu,
C., Manis, J.P., Horner, J., DePinho, R.A., and Alt, F.W. (2000). DNA ligase IV
deficiency in mice leads to defective neurogenesis and embryonic lethality
via the p53 pathway. Mol. Cell 5, 993–1002.
Fugmann, S.D., Lee, A.I., Shockett, P.E., Villey, I.J., and Schatz, D.G. (2000).
The RAG proteins and V(D)J recombination: complexes, ends, and transpo-
sition. Annu. Rev. Immunol. 18, 495–527.
Gao, Y., Ferguson, D.O., Xie, W., Manis, J.P., Sekiguchi, J., Frank, K.M.,
Chaudhuri, J., Horner, J., DePinho, R.A., and Alt, F.W. (2000). Interplay of
p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability
and development. Nature 404, 897–900.
Gladdy, R.A., Taylor, M.D., Williams, C.J., Grandal, I., Karaskova, J., Squire,
J.A., Rutka, J.T., Guidos, C.J., and Danska, J.S. (2003). The RAG-1/2 endo-
nuclease causes genomic instability and controls CNS complications of lym-
phoblastic leukemia in p53/Prkdc-deficient mice. Cancer Cell 3, 37–50.
Godfrey, D.I., Kennedy, J., Mombaerts, P., Tonegawa, S., and Zlotnik, A.
(1994). Onset of TCR-b gene rearrangement and role of TCR-b expression
during CD32CD42CD82 thymocyte differentiation. J. Immunol. 152, 4783–
4792.119
A R T I C L EGreaves, M.F., and Wiemels, J. (2003). Origins of chromosome transloca-
tions in childhood leukaemia. Nat. Rev. Cancer 3, 639–649.
Gu, Y., Seidl, K.J., Rathbun, G.A., Zhu, C., Manis, J.P., van der Stoep, N., Da-
vidson, L., Cheng, H.L., Sekiguchi, J.M., Frank, K., et al. (1997). Growth retar-
dation and leaky SCID phenotype of Ku70-deficient mice. Immunity 7, 653–
665.
Guidos, C.J., Williams, C.J., Grandal, I., Knowles, G., Huang, M.T.F., and
Danska, J.S. (1996). V(D)J recombination activates a p53-dependent DNA
damage checkpoint in scid lymphocyte precursors. Genes Dev. 10, 2038–
2054.
Haks, M.C., Krimpenfort, P., van den Brakel, J.H., and Kruisbeek, A.M.
(1999). Pre-TCR signaling and inactivation of p53 induces crucial cell survival
pathways in pre-T cells. Immunity 11, 91–101.
Haks, M.C., Belkowski, S.M., Ciofani, M., Rhodes, M., Lefebvre, J.M., Trop,
S., Hugo, P., Zuniga-Pflucker, J.C., and Wiest, D.L. (2003). Low activation
threshold as a mechanism for ligand-independent signaling in pre-T cells.
J. Immunol. 170, 2853–2861.
Jacks, T., Remington, L., Williams, B.O., Schmitt, E.M., Halachmi, S., Bron-
son, R.T., and Weinberg, R.A. (1994). Tumor spectrum analysis in p53-mu-
tant mice. Curr. Biol 4, 1–7.
Jhappan, C., Morsle, H.C., III, Fleischmann, R.D., Gottesman, M.M., and
Merlino, G. (1997). DNA-PKcs: a T-cell tumour suppressor encoded at the
mouse scid locus. Nat. Genet. 17, 483–486.
Jiang, D., Lenardo,M.J., and Zuniga-Pflucker, J.C. (1996). p53 preventsmat-
uration to the CD4+CD8+ stage of thymocyte differentiation in the absence of
T cell receptor rearrangement. J. Exp. Med. 183, 1923–1928.
Khanna, K.K., and Jackson, S.P. (2001). DNA double-strand breaks: signal-
ing, repair and the cancer connection. Nat. Genet. 27, 247–254.
Leduc, I., Hempel,W.M.,Mathieu, N., Verthuy, C., Bouvier, G.,Watrin, F., and
Ferrier, P. (2000). T cell development in TCRb enhancer-deleted mice: impli-
cations for ab T cell lineage commitment and differentiation. J. Immunol. 165,
1364–1373.
Lee, G.S., Neiditch, M.B., Salus, S.S., and Roth, D.B. (2004). RAG proteins
shepherd double-strand breaks to a specific pathway, suppressing error-
prone repair, but RAG nicking initiates homologous recombination. Cell
117, 171–184.
Levelt, C.N., and Eichmann, K. (1995). Receptors and signals in early thymic
selection. Immunity 3, 667–672.
Lewis, S.M., Agard, E., Suh, S., and Czyzyk, L. (1997). Cryptic signals and the
fidelity of V(D)J joining. Mol. Cell. Biol. 17, 3125–3136.
Li, G.C., Ouyang, H., Li, X., Nagasawa, H., Little, J.B., Chen, D.J., Ling, C.C.,
Fuks, Z., and Cordon-Cardo, C. (1998). Ku70: A candidate tumor suppressor
gene for murine T cell lymphoma. Mol. Cell 2, 1–8.
Liao, M.J., Zhang, X.X., Hill, R., Gao, J., Qumsiyeh, M.B., Nichols, W., and
Van Dyke, T. (1998). No requirement for V(D)J recombination in p53-deficient
thymic lymphoma. Mol. Cell. Biol. 18, 3495–3501.
Marculescu, R., Le, T., Simon, P., Jaeger, U., and Nadel, B. (2002). V(D)J-me-
diated translocations in lymphoid neoplasms: a functional assessment of ge-
nomic instability by cryptic sites. J. Exp. Med. 195, 85–98.
Mathieu, N., Hempel, W.M., Spicuglia, S., Verthuy, C., and Ferrier, P. (2000).
Chromatin remodeling by the T cell receptor (TCR)-b gene enhancer during
early T cell development: Implications for the control of TCR-b locus recom-
bination. J. Exp. Med. 192, 625–636.
McBlane, J.F., van Gent, D.C., Ramsden, D.A., Romeo, C., Cuomo, C.A.,
Gellert, M., and Oettinger, M.A. (1995). Cleavage at a V(D)J recombination
signal requires only RAG1 and RAG2 proteins and occurs in two steps.
Cell 83, 387–395.120Monni, O., and Knuutila, S. (2001). 11q deletions in hematological malignan-
cies. Leuk. Lymphoma 40, 259–266.
Monroe, R.J., Seidl, K.J., Gaertner, F., Han, S., Chen, F., Sekiguchi, J., Wang,
J., Ferrini, R., Davidson, L., Kelsoe, G., and Alt, F.W. (1999). RAG2:GFP
knockin mice reveal novel aspects of RAG2 expression in primary and pe-
ripheral lymphoid tissues. Immunity 11, 201–212.
Nacht, M., and Jacks, T. (1998). V(D)J recombination is not required for the
development of lymphoma in p53-deficient mice. Cell Growth Differ. 9,
131–138.
Nacht, M., Strasser, A., Chan, Y.R., Harris, A.W., Schlissel, M., Bronson, R.T.,
and Jacks, T. (1996). Mutations in the p53 and SCID genes cooperate in tu-
morigenesis. Genes Dev. 10, 2055–2066.
Oikawa, T., and Yamada, T. (2003). Molecular biology of the Ets family of
transcription factors. Gene 303, 11–34.
Raghavan, S.C., Swanson, P.C., Wu, X., Hsieh, C.L., and Lieber, M.R. (2004).
A non-B-DNA structure at the Bcl-2major breakpoint region is cleaved by the
RAG complex. Nature 428, 88–93.
Roth, D.B., Menetski, J.P., Nakajima, P.B., Bosma, M.J., and Gellert, M.
(1992). V(D)J recombination: Broken DNA molecules with covalently sealed
(Hairpin) coding ends in scid mouse thymocytes. Cell 70, 983–991.
Rothenberg, E.V., and Taghon, T. (2005). Molecular genetics of T cell devel-
opment. Annu. Rev. Immunol. 23, 601–649.
Ryu, C.J., Haines, B.B., Draganov, D.D., Kang, Y.H., Whitehurst, C.E.,
Schmidt, T., Hog, H.J., and Chen, J. (2003). The T cell receptor b enhancer
promotes access and pairing of Db and Jb gene segments during V(D)J re-
combination. Proc. Natl. Acad. Sci. USA 100, 13465–13470.
Sakata, J., Inoue, J., Ohi, H., Kosugi-Okano, H., Mishima, Y., Hatakeyama,
K., Niwa, O., and Kominami, R. (2004). Involvement of V(D)J recombinase
in the generation of intragenic deletions in the Rit1/Bcl11b tumor suppressor
gene in g-ray-induced thymic lymphomas and in normal thymus of the
mouse. Carcinogenesis 25, 1069–1075.
Schlissel, M., Constantinescu, A., Morrow, T., Baxter, M., and Peng, A.
(1993). Double-strand signal sequence breaks in V(D)J recombination are
blunt, 50-phosphorylated, RAG-dependent and cell cycle regulated. Genes
Dev. 7, 2520–2532.
Stilgenbauer, S., Schaffner, C., Litterst, A., Liebisch, P., Gilad, S., Bar-Shira,
A., James, M.R., Lichter, P., and Dohner, H. (1997). Biallelic mutations in the
ATM gene in T-prolymphocytic leukemia. Nat. Med. 3, 1155–1159.
Tanaka, K., Eguchi, M., Eguchi-Ishimae,M., Hasegawa, A., Ohgami, A., Kiku-
chi, M., Kyo, T., Asaoku, H., Dohy, H., and Kamada, N. (2001). Restricted
chromosome breakpoint sites on 11q22-q23.1 and 11q25 in various hemato-
logicalmalignancies withoutMLL/ALL-1 gene rearrangement. Cancer Genet.
Cytogenet. 124, 27–35.
Tycko, B., and Sklar, J. (1990). Chromosomal translocations in lymphoid
neoplasia: A reappraisal of the recombinase model. Cancer Cells 2, 1–8.
Vanasse, G.J., Concannon, P., and Willerford, D.M. (1999). Regulated geno-
mic instability and neoplasia in the lymphoid lineage. Blood 94, 3997–4010.
van Gent, D.C., Hoeijmakers, J.H., and Kanaar, R. (2001). Chromosomal sta-
bility and the DNA double-stranded break connection. Nat. Rev. Genet. 2,
196–206.
Whitehurst, C., Chattopadhyay, S., and Chen, J. (1999). Control of V(D)J re-
combinational accessibility of the Db1 gene segment at the TCRb locus by
a germline promoter. Immunity 10, 313–322.
Zhu, C., Mills, K.D., Ferguson, D.O., Lee, C., Manis, J., Fleming, J., Gao, Y.,
Morton, C.C., and Alt, F.W. (2002). Unrepaired DNA breaks in p53-deficient
cells lead to oncogenic gene amplification subsequent to translocations.
Cell 109, 811–821.CANCER CELL FEBRUARY 2006
